Predictors of Success After Intercostal Nerve Radiofrequency Treatment for Intercostal Neuralgia (NCT07367152) | Clinical Trial Compass
CompletedNot Applicable
Predictors of Success After Intercostal Nerve Radiofrequency Treatment for Intercostal Neuralgia
Turkey (Türkiye)60 participantsStarted 2018-01-01
Plain-language summary
This retrospective cohort study will review medical records of patients treated with intercostal nerve radiofrequency for intercostal neuralgia. The goal is to identify patient and clinical factors that are associated with treatment success after the procedure. Outcomes will be assessed using pain measures documented during routine follow-up visits, along with any recorded adverse events. No additional visits, tests, or interventions are required because this study uses previously collected clinical data.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years.
* Diagnosis of intercostal neuralgia (post-traumatic, postherpetic, or idiopathic) with thoracic neuropathic pain for at least 1 month
* Underwent ultrasound-guided intercostal nerve radiofrequency treatment (conventional radiofrequency ablation \[CRF\] or pulsed radiofrequency \[PRF\]) as part of routine clinical care
* Documented baseline NRS-11 pain score prior to the procedure and follow-up NRS-11 data available through at least 6 months after treatment.
Exclusion Criteria:
* Thoracic pain attributable to malignancy-related causes (e.g., active malignant invasion, spinal metastasis) or an intrathoracic mass
* History of thoracic surgery at the corresponding thoracic dermatome level (e.g., thoracotomy or VATS)
* Prior radiofrequency treatment at the same intercostal nerve site
* Receipt of other interventional treatments targeting the intercostal nerve during the study period (e.g., cryoablation or chemical neurolysis)
* Insufficient follow-up data (less than 6 months of follow-up NRS-11 documentation).
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Treatment response at 6 months (IMMPACT-defined responder rate)